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Introduction
Atrial fibrillation (AF) is one of the most common cardiac arrhy-
thmias. Over time, it has been understood as a prothrombotic dis-
ease.1)2) According to Virchow’s triad, three conditions must be 
present for thrombosis to occur, and all of the three conditions are 
present in AF: loss of atrial contractility, endocardial damage, and 
abnormalities in hemostatic variables.3) However, although both atria 
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Background and Objectives: It has been known that the dominant driver of atrial fibrillation (AF) exists in the left atrium (LA) and the 
incidence of systemic thromboembolism is higher than that of pulmonary thromboembolism in patients with AF. Therefore, we hypothe-
sized that histological and biochemical characteristics of the LA and the right atrium (RA) are different in patients with mitral valvular AF.
Subjects and Methods: We analyzed the histology and messenger ribonucleic acid (mRNA) or protein expression associated with endo-
thelial function and thrombogenesis in 33 human atrial appendage tissues (20 LA tissues, 13 RA tissues) taken from 25 patients 
{57.7±11.3 years old, 44% males, AF: sinus rhythm (SR)=17:8} with mitral valve disease. We also performed whole mRNA quantification 
in 8 tissues (both LA and RA tissues from 4 patients) by using next generation sequencing (NGS). 
Results: 1) The degree of fibrosis (p=0.001) and subendocardial smooth muscle thickness (p=0.004) were significantly greater in the LA 
than in the RA. 2) More advanced matrix fibrosis was found in the LA of patients with AF than in the LA of patients with SR (p=0.046), 
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let-derived growth factor, myeloperoxidase, or NCX, except for higher mRNA expression of HCN4 in the RA (qRT-PCR, p=0.026) and that 
of KCNN1 in the LA (NGS, p=0.016). 
Conclusion: More advanced matrix and subendocardial remodeling were noticed in the LA than in the RA in patients with mitral valvular 
AF. However, the expressions of tissue factors associated with thrombogenesis were not significantly different between the RA and the 
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fibrillate in AF, growing evidence suggests that the majority of th-
rombi originate in the left atrium (LA). Several studies have investi-
gated the characteristics that make the LA more prone to throm-
bosis than the right atrium (RA) during AF. For example, Cai et al.4) 
have reported that the level of nitric oxide (NO), a vasodilator and an 
antithrombotic agent, was markedly decreased in porcine LA and 
LA appendage (LAA) during AF compared to that in LA showing si-
nus rhythm (SR), RA, and aorta. In line with the results of this study, 
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Dudley et al.5) found that the superoxide (O2
-) level was increased in 
the LA, suggesting greater NO degradation in the LA than in the 
RA during AF. Downstream of NO, several factors are known to be 
involved in inflammation, thrombosis, as well as in remodeling. Stro-
mal cell-derived factor-1 (SDF-1)6) and endothelin-1 (ET-1)7) are pro-
moters of platelet activity;8-10) E-selectin and CD31 (PECAM) enable 
platelet aggregation and activation;11)12) and platelet-derived growth 
factor (PDGF) mediates fibrosis.13) All of these molecules are, at least 
in part, regulated by NO.6)14) In addition, myeloperoxidase (MPO) was 
also recently found to mediate structural as well as electrical remo-
deling of atria during AF.15) While a number of studies have attempt-
ed to compare between the LA and the RA, differences between the 
two chambers in terms of vessel wall characteristics still remain elu-
sive. Therefore, in this study, we aimed to compare the degree of 
fibrosis and expression of NO-mediated platelet activating proteins 
(pNF-κβ, ET-1, SDF-1), inducible NO synthase (iNOS), proinflamma-
tory proteins (E-selectin, CD31), and profibrotic proteins (MPO, 
PDGF) between the LA and the RA in an attempt to characterize the 
endocardial changes specific to the LA during AF, and to elucidate 
the possible mechanism for thrombosis in fibrillating LA (Fig. 1). 
Subjects and Methods
Patient selection
The study protocol was approved by the Institutional Review 
Board of Severance Cardiovascular Hospital, Yonsei University He-
alth System. All of the patients provided written informed consent. 
The study enrolled 25 patients (mean age 57.7±11.3 years, 44% 
males), who underwent mitral valve surgery and biopsy of the LA or 
the RA appendage (Table 1). Among these patients, 23 had AF and 
10 were in SR. Comprehensive transthoracic echocardiography was 
performed using commercially available devices (Sonos 5500; Phil-
ips Medical System, Andover, MA, USA, or Vivid 7; GE Vingmed Ul-
trasound, Horten, Norway). Standard M-mode, two-dimensional and 
Doppler images were acquired in the parasternal and apical views. 
Left atrial (LA) anterior-posterior diameter was measured, and left 
ventricular (LV) end-diastolic dimension (LVEDD) and LV end-systolic 
dimension (LVESD) were calculated from two-dimensional images 
using the modified Quinones method. Full wall thickness specimens 
were excised from the LA or the RA appendages. All of the myocar-
dial specimens were fixed in 70% alcohol and 10% formalin solu-
tion immediately after excision.
Immunohistochemical studies
Multiple 5 μm thick serial sections were used. Masson’s trichrome 
(MT) stain was used to determine the presence and degree of fibro-
sis. Immunohistochemical staining was performed using an avidin-
biotin peroxidase system (Dako, Carpinteria, CA, USA). Paraffin-em-
bedded tissue sections were deparaffinized and then washed with 
phosphate-buffered saline (PBS). Hydrogen peroxidase block (Dako, 
Carpinteria, CA, USA) was placed on the sections for 10 minutes, and 
the slides were washed in PBS. Protein block (Dako, Carpinteria, CA, 
USA) was placed on the sections for 30 minutes. Primary antibodies 
were then incubated for 90 minutes at room temperature (approx. 
25°C). Antibodies for α-SMA (1:500 dilution, rabbit anti-human 
polyclonal; Abcam) were used to stain the smooth muscle. After in-
cubation, the slides were washed in PBS, and the appropriate sec-
ondary antibody (Dako, Carpinteria, CA, USA) was placed on the sec-
tions for 30 minutes. The sections were washed again in PBS, and 
the appropriate chromagen was added to each specimen. Smooth 
mucle cells and gap junctions were stained brown with 3,3’-diami-
nobenzidine (DAB). Cell nuclei were marked by placing the speci-
mens in hematoxylin (Merck) for 1 minute. The specimens were then 
dehydrated in alcohol, mounted, and examined under light micros-
copy. The specimens stained with DAB were examined by light mi-
croscopy and virtual microscopy. Histopathological slides were an-
alyzed by use of a computer-assisted morphometric analysis system 
(Image-Pro Plus 6.0; Media Cybernetics, Silver Spring, MD, USA). 
The selection and analyses of virtual microscopic images were 
performed by a single technician, who was blinded to the experi-
mental information of histological slides obtained with a consis-
tent method. To quantify the fibrotic area, we selected the virtual 
microscopic fields with the fibrotic area on MT staining, and took 
images at a 160 objective in the quadrants of each slide. In each of 
the four fields, the smooth muscle area was identified as fibrillar 
structures positive for α-SMA immunohistostaining, between myo-
cardial cells, which were larger than 10 μm and stained brown (RGB 
values: Red 22–125, Green 4–77, and Blue 4–55). In the endocardium, 
Platelet aggregation
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Fig. 1. Diagram of the mechanisms of multiple tissue factors associated 
with thrombosis. NO: nitric oxide, TNF: tumor necrosis factor, IL: interleukin, 
Ap-1/Sp-1: Ap-1/Sp-1 transcription factors, Egr-1: early growth response 
protein-1, SDF: stromal cell-derived factor, PECAM: platelet endothelial cell 
adhesion molecule, PDGF: platelet-derived growth factor, BMEPC: bone 
marrow-derived endothelial progenitor cells.
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Table 1. Clinical characteristics
Patient # Age Sex Rhythm
Existing 
conditions
Operation
BMI
(kg/m2)
LA size
(mm)
EF (%)
LVEDD
(mm)
LVESD
(mm)
LA
1 60 M AF MS MVR 26.13 76 58 58 42
2 51 M AF MSR MVR 23.31 77 63 60 41
3 47 M AF MS, AR MVR 21.56 59 69 58 37
4 62 M AF MS MVR 24.91 79 52 58 40
5 67 M AF MS MVR 21.30 66 51 57 42
6 63 F AF MS, DM, TR MVR 14.27 41 73 41 25
7 74 F AF MR (MVP) MV repair 19.15 66 74 62 37
8 60 F AF AS, MS DVR 24.03 68 61 57 40
9 73 F AF MS, TR MVR 24.03 65 68 45 29
10 67 F AF MS MVR 24.24 60 56 49 36
11 63 F AF MS MVR 26.04 58 71 43 27
12 52 F AF MS MVR 24.56 55 62 42 29
13 61 F AF MR (MVP), 
ASD
MV repair 18.13 54 84 45 23
14 67 F AF MS MVR 20.70 88 70 57 36
15 53 M SR MS MVR 28.40 52 74 52 31
16 54 M SR MS MVR 23.12 46 68 45 29
17 51 M SR MR (MVP) MV repair 24.16 52 59 66 47
18 39 M SR MR, TR MVR 21.30 66 45 54 42
19 38 F SR MR (MVP) MVR 26.78 42 66 59 39
20 76 F SR MR, AR MV repair 20.09 47 60 62 44
58.90±10.69 22.81±3.32 60.85±12.81 64.20±9.33 53.50±7.64 35.80±6.89
RA
3* 47 M AF MS, AR MVR 21.56 59 69 58 37
4* 62 M AF MS MVR 24.91 79 52 58 40
6* 63 F AF MS MVR 14.27 41 73 41 25
7* 74 F AF MR (MVP) MV repair 19.15 66 74 62 37
11* 63 F AF MS MVR 26.04 58 71 43 27
13* 61 F AF MR (MVP), 
ASD
MV repair 18.13 54 84 45 23
16* 54 M SR MS MVR 23.12 46 68 45 29
17* 51 M SR MR (MVP) MV repair 24.16 52 59 66 47
21 35 M AF MS, TR MVR 19.66 57 48 57 43
22 73 M AF MR, TR MV repair 21.67 62 35 68 57
23 58 F AF MR, TR MVR 20.28 63 57 62 45
24 35 F SR MS MVR 17.85 41 55 46 34
25 50 F SR MR MVR 24.14 45 67 52 34
55.85±12.26 21.15±3.35 55.62±10.87 62.46±13.06 54.08±9.26 36.77±9.71
*Overlapping patients in both LA and RA groups. LA: left atrium, RA: right atrium, M: male, F: female, AF: atrial fibrillation, SR: sinus rhythm, MS: mitral ste-
nosis, MR: mitral regurgitation, MVP: mitral valve repair, AR: aortic regurgitation, TR: tricuspid regurgitation, ASD: atrial septal defect, MVR: mitral valve re-
placement, MV repair: mitral valve repair, DVR: double valve replacement, EF: ejection fraction, LVEDD: left ventricular end-diastolic dimension, LVESD: left 
ventricular end-systolic dimension, BMI: body mass index
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we measured the subendocardial thickness and smooth muscle 
thickness maintaining distance of 200 μm. The percent immunos-
tained areas and distance of the fibrotic area, and α-SMA-positive 
smooth muscle cells were quantified using Image Pro software 6.0 
(Media Cybernetics Inc., Silver Spring, MD, USA). The virtual histology 
was then analyzed as described before.16) The percent area of fibrosis 
was quantified with MT staining utilizing the Image Pro software. 
Real-time quantitative polymerase chain reaction
The method used to quantitate cDNA was the quantitative real-
time polymerase chain reaction (PCR) method. The levels of cDNA 
were determined via fluorescence by using the thermal cycler dur-
ing the PCR cycle. The real-time PCR reactions were performed us-
ing SYBR1 Green Kit in a 20 μL reaction volume containing 50 ng of 
cDNA. PCR reactions were carried out using a sequence detection 
system. Thermal cycling and SYBR Green fluorescence detection 
were performed using a real-time PCR thermal cycler (ABI PRISM 
7500 Sequence Detection System, Applied Biosystems, Foster City, 
CA, USA). The primers were designed for HCN4 (Forward: GCAGC 
GCATCCACGACTAC, Reverse: TTAGCTCGCCCAGGATGCT), and NCX 
(Forward: TTCCAGAATGATGAAATTGTGAAGAT, Reverse: TCCTCAAG 
CACAAGGGAGAAAC) using the primer express software. The sodium 
calcium exchanger (NCX) forward primer (5’ to 3’) was TTCCAGA 
ATGATGAAATTGTGAAGAT and the reverse primer (5’ to 3’) was TCC 
TCAAGCACAAGGGAGAAAC. Then, 20 μL PCR reactions were pre-
pared in 96 well plates with a computer-assisted robotic and liquid 
handling automated workstation. We chose HCN4 and NCX because 
they play important roles in arrhythmogenicity and embryological 
development of the RA and the LA. Thermal cycling conditions were 
as follows: 50°C for 2 minutes and 95°C for 10 minutes, followed 
Table 2. Clinical and histological characteristics of the LA and the RA
  LA (n=20) RA (n=13) p
Age 58.90±10.69 55.85±12.26 0.455
Sex (male, %) 45.00 42.86 0.950
BMI (kg/m2) 22.81±3.32 21.15±3.35 0.172
BSA (m2) 1.64±0.22 1.59±0.23 0.529
Echocardiographic findings
LA size (mm) 60.85±12.81 55.62±10.87 0.234
LA volume (mL) 179.69±101.22 139.75±67.97 0.221
LA volume Index (mL/m2) 130.70±73.20 91.84±33.64 0.132
LVEF (%) 64.20±9.33 62.46±13.06 0.658
E/Em 16.39±5.89 18.46±5.17 0.554
LVEDD (mm) 53.50±7.64 54.08±9.26 0.847
LVESD (mm) 35.80±6.89 36.77±9.71 0.739
Histologic analyses
Fibrosis (MT) (% area) 23.78±10.22 11.33±6.37 0.001
Subendocardial smooth muscle area (%) 4.39±5.40 0.32±0.58 0.011
Subendocardial smooth muscle thickness (mm) 0.16±0.17 0.01±0.01 0.004
Western blot
pNF-kβ 1.22±0.38 1.02±0.31 0.198
CD31 0.70±0.20 0.78±0.23 0.420
E-selectin 0.97±0.42 0.17±0.35 0.145
iNOS 0.59±0.39 0.62±0.44 0.876
SDF-1α 0.74±0.37 0.61±0.22 0.380
Endothelin-1 0.86±0.27 0.71±0.24 0.218
PDGF 0.53±0.25 0.45±0.06 0.528
MPO 0.74±0.28 0.93±0.55 0.508
Real-time PCR
2-ΔCt NCX 0.012±0.012 0.007±0.005 0.139
2-ΔCt HCN4 0.011±0.010 0.027±0.028 0.026
LA: left atrium, RA: right atrium, BMI: body mass index, BSA: body surface area, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end-diastolic 
dimension, LVESD: left ventricular end-systolic dimension, MT: Masson’s trichrome, iNOS: inducible NO synthase, SDF-1: stromal cell-derived factor-1, 
PDGF: platelet-derived growth factor, MPO: myeloperoxidase, PCR: polymerase chain reaction
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by 40 cycles at 95°C for 30 seconds, 60°C for 30 seconds and 72°C 
for 1 minute. A melting curve analysis was performed after the final 
PCR cycle to evaluate the presence of nonspecific PCR products 
and primer dimers. During the initial optimization run, four-fold se-
rial dilution was employed to demonstrate the linear amplification 
range for each gene. The threshold cycle (Ct) represents the PCR cy-
cle during which an increase in SYBR Green fluorescence above the 
baseline signal can be detected first. For each sample, the amount 
of messenger ribonucleic acid (mRNA) was quantified relative to 
0.5 μg of total RNA applied by real-time PCR. Relative quantitation 
was performed by normalizing Ct values of each sample gene to Ct 
values of the housekeeping gene (ΔCt). ΔCt corresponds to the dif-
ference between the Ct of the gene of interest and the Ct of the 
housekeeping gene. Also, we tried to perform RNA Sequencing on 
transformed human tissues.
Next generation sequencing
To compare the amount of proteins and mRNA, we performed 
whole mRNA quantification in 8 tissues (4 from the LA, 4 from the 
RA) by using the next generation sequencing (NGS) method. Se-
quencing library was prepared using the NEBNext RNA prep kit 
(NEB, MA, USA). Briefly, the poly-A containing mRNA molecules 
were purified using poly-T oligonucleotide-attached magnetic 
beads. The mRNA was fragmented into small pieces and copied into 
cDNA. Library preparation process including end-repairing and 
subsequent adapter ligation produced the final library with size 
ranging from 250–350 bp. Sequencing was performed using HiSeq 
2500 (Illumina, CA, USA) with the rapid run 150 bp PE mode.17)
Western blot analysis
For protein analysis, previously excised human LA tissues stored 
in liquid nitrogen (-80°C) were used. The tissue specimens were 
homogenized and lysed in a mixture of 50 mmol Tris (pH 7.4), 5 
mM EDTA (pH 8.0), and 1% Triton X-100. The samples were centri-
fuged at 13000 rpm for 1 hour at 4°C to separate the supernatant. 
Protein content was determined by the BCA assay at 55°C. Extracts 
were separated by SDS-polyacrylamide gel electrophoresis and 
transferred to polyvinylidene difluoride membranes. After blocking 
in TBS-Tween 20 (TBS-T, 0.1% tween 20) containing 5% non-fat dry 
milk, the membrane was incubated overnight with primary anti-
bodies; pNF-κβ (1:1000 dilution, mouse antihuman monoclonal; Cell 
Signaling), CD31 (1:1000 dilution, rabbit antihuman polyclonal; Ab-
cam, Cambridge, MA, USA), E-selectin (1:1000 dilution, rabbit anti-
human polyclonal; Abcam, Cambridge, MA, USA), iNOS (1:1000 di-
lution, Abcam, Cambridge, MA, USA), SDF-1α (1:1000 dilution, rabbit 
antihuman polyclonal; Abcam, Cambridge, MA, USA), ET-1 (1:1000 
dilution, mouse antihuman monoclonal; Thermo Scientific, Hudson, 
NH, USA), PDGF (1:500 dilution, rabbit antihuman polyclonal; Pierce 
Biotechnology, Rockford, IL, USA), and MPO (1:1000 dilution, rabbit 
antihuman polyclonal; Abcam, Cambridge, MA, USA). The primary 
antibody incubation was followed by incubation with HRP-conju-
gated secondary antibodies (Dako, Carpinteria, CA, USA). The anti-
gen-antibody bands were detected using the enhanced chemilumi-
nescence reagent kit (Millipore Co, Bedford, MA, USA) and quan-
tified by densitometry.
Data analysis
Data are expressed as mean±SD. We conducted several comparison 
MT stain
α-SMA
A  
B  
Fig. 2. Masson’s trichrome (MT) staining (A) and α-smooth muscle actin (SMA) staining (B) of AF-LA, SR-LA, AF-RA, and SR-RA. AF: atrial fibrillation, LA: left 
atrium, RA: right atrium, SR: sinus rhythm.
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analyses on thickness of the subendocardial smooth muscle layer, 
the fibrotic area, the density of the protein bands in the western blot 
analysis, and real-time PCR result in various cohorts. The statistical 
significance of these comparisons was assessed using the Stu-
dent’s t-test or the paired t-test. p less than 0.05 were considered 
statistically significant.
Results
Severe remodeling of the left atrium compared to the right 
atrium in patients with mitral valve disease
The baseline characteristics of enrolled patients are summarized 
in Table 1. We divided the patients into a LA group (n=20) and a 
RA group (n=13) and compared their clinical and histological char-
acteristics (Table 2). The data showed no significant difference in 
their clinical and echocardiographic characteristics. The percent ar-
eas of subendocardial fibrosis (MT stain, p=0.001) and subendocar-
dial smooth muscle layer (α-SMA immunostaining, p=0.011) were 
greater in the LA than in the RA (Fig. 2). Subendocardial smooth 
muscle thickness was also higher in the LA than in the RA; thus de-
monstrating greater structural remodeling in the LA than in the RA 
(p=0.004) (Table 2).
Differential degree of left atrium remodeling in patients with
atrial fibrillation and patients in sinus rhythm 
We divided the patients with mitral valve disease into patients 
Table 3. Clinical and histological characteristics of AF patients’ LA and RA and that of SR controls’ LA and RA
 
AF (n=23)
p
SR (n=10)
p
LA (n=14) RA (n=9) LA (n=6) RA (n=4)
Age 61.93±7.83 59.56±12.17 0.574 51.83±13.76 47.50±8.51 0.593
Sex (male, %) 44.45 35.71 0.692 66.67 50.00 0.645
BMI (kg/m2) 21.31±3.37 20.63±3.58 0.264 23.97±3.18 22.32±3.02 0.435
BSA (m2) 1.59±0.20 1.55±0.23 0.658 1.76±0.23 1.68±0.24 0.623
Echocardiographic findings
LA size (mm) 65.14±12.11 59.89±10.13 0.293 50.83±8.35 46.00±4.55 0.327
LA volume (mL) 206.19±108.90 152.93±75.62 0.215 117.87±39.38 110.08±39.20 0.767
LA volume Index (mL/m2) 126.35±62.76 95.28±35.98 0.194 68.06±21.07* 64.90±17.77 0.812
LVEF (%) 64.71±10.07 62.56±15.52 0.689 63.00±8.05 62.25±6.29 0.880
LVEDD (mm) 52.07±7.52 54.89±9.55 0.438 56.83±7.47 52.25±9.67 0.421
LVESD (mm) 34.57±6.63 37.11±10.89 0.492 38.67±7.23 36.00±7.70 0.592
Histologic analyses
Fibrosis (MT) (% area) 26.73±9.22 11.06±7.69 0.001 16.91±9.75* 11.87±3.22 0.355
Subendocardial smooth muscle area (%) 5.74±5.92 0.39±0.69 0.014 1.23±1.66 0.16±0.20 0.242
Subendocardial smooth muscle 
  thickness (mm)
0.21±0.19 0.01±0.01 0.005 0.05±0.06 0.01±0.01 0.192
Western blot
pNF-kβ 1.26±0.41 0.97±0.25 0.139 1.09±0.30 1.11±0.45 0.939
CD31 0.73±0.22 0.24±0.72 0.928 0.62±0.10 0.90±0.18 0.074
E-selectin 0.97±0.47 0.65±0.31 0.163 0.98±0.18 0.84±0.48 0.660
iNOS 0.55±0.38 0.45±0.34 0.607 0.79±0.58 1.13±0.32** 0.548
SDF-1α 0.75±0.41 0.59±0.27 0.423 0.70±0.15 0.66±0.10 0.720
Endothelin-1 0.83±0.28 0.70±0.27 0.349 1.02±0.12 0.76±0.21 0.267
PDGF 0.63±0.29 0.44±0.03 0.320 0.37±0.07 0.46±0.12 0.429
MPO 0.68±0.37 0.71±0.40 0.943 0.82±0.06 1.26±0.74 0.486
Real-time PCR
2-ΔCt NCX 0.014±0.014 0.008±0.006 0.232 0.008±0.008 0.004±0.002 0.355
2-ΔCt HCN4 0.012±0.012 0.026±0.026 0.088 0.009±0.006 0.028±0.035 0.208
*p<0.05 AF LA vs. SR LA, **p<0.05 AF RA vs. SR RA. AF: atrial fibrillation, LA: left atrium, RA: right atrium, SR: sinus rhythm, BMI: body mass index, BSA: 
body surface area, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension, 
MT: Masson’s trichrome, iNOS: inducible NO synthase, SDF-1: stromal cell-derived factor-1, PDGF: platelet-derived growth factor, MPO: myeloperoxidase, 
PCR: polymerase chain reaction
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with AF and patients in SR, and then, subdivided the AF and SR 
groups into the LA and RA groups (Table 3). The clinical analysis 
revealed that the 4 groups showed no significant differences in sex, 
age, LA size, and LA volume. In terms of the degree of fibrosis, LA 
of the patients with AF showed more advanced interstitial fibrosis 
than LA of the patients in SR (p=0.046). But, there was no difference 
in the degree of fibrosis in the RA regardless of the rhythm status 
(p=0.355). Among the patients with mitral valvular AF, the degree of 
fibrosis (p=0.001), percent area (p=0.014) and thickness (p=0.005) 
of the subendocardial smooth muscle layer were significantly great-
er in the LA than in the RA (Fig. 3).
The messenger ribonucleic acid or protein expression level 
in the left atrium and right atrium tissues 
We have summarized the tissue characteristics based on the 
protein and mRNA expressions in Table 2. The protein expressions 
analyzed by western blot revealed that there were no significant 
differences in pNF-κB, CD31, E-selectin, iNOS, SDF-1α, ET-1, PDGF, 
and MPO expressions between the LA and the RA groups (Fig. 4). 
The tissue expression levels of thrombogenicity-related proteins 
were not significantly different among the 4 groups; AF vs. SR and 
LA vs. RA, except for the lower tissue level of iNOS in the LA of pa-
tients in SR than in the RA of patients in SR (p=0.048) (Table 3). In 
terms of mRNA expression, NGS for mRNA was conducted using 8 
tissues taken from 4 patients (2 AF and 2 patients remained in si-
nus rhythm), and all these were patient-matched RA (n=4) and LA 
Fig. 3. Scatter plots of fibrosis area (%) and thickness of the subendocar-
dial smooth muscle layer (mm) for the LA and RA. Most of the remodeling 
occurred in the fibrillating LA followed by LA showing sinus rhythm. AF: 
atrial fibrillation, LA: left atrium, RA: right atrium, SR: sinus rhythm.
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Fig. 4. Western blot analysis of pNF-κB, CD31, E-selectin, iNOS, SDF-1α, Endothelin-1, PDGF, and MPO showed that the protein expression levels were not 
significantly different between the LA and the RA. LA: left atrium, RA: right atrium, iNOS: inducible NO synthase, SDF-1: stromal cell-derived factor-1, 
PDGF: platelet-derived growth factor, MPO: myeloperoxidase.
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tissues (n=4). It showed no significant difference in the mRNA lev-
els of thrombogenicity-related proteins between the LA and the 
RA tissues or between patients with AF and patients in SR (Table 4). 
The mRNA expression of HCN4, a membrane ion channel protein, 
as measured by real time-PCR was significantly higher in RA tis-
sues than in LA tissues (p=0.026) (Table 2), but that of KCNN1 (cal-
cium activated potassium channel subfamily) was higher in LA tis-
sues than in RA tissues (p=0.016) (Table 4). The mRNA expression 
of NCX was not significantly different between the LA and RA tis-
sues (p=0.139).
Discussion
In the current study, we report that fibrosis and subendocardial 
smooth muscle thickness were significantly greater in the LA than 
in the RA of patients with AF. Also, matrix fibrosis was more ad-
vanced in the LA of patients with AF than that in the LA of patients 
in SR. However, we did not observe any difference in the factors 
that contribute to vessel wall abnormality in thrombosis between 
the LA and the RA. To the best of our knowledge, this is the first 
study to systematically analyze the differences in endocardial char-
acteristics between the LA and the RA in patients with AF and to 
exclude tissue factors as a cause of enhanced thrombogenesis in 
the fibrillating LA. 
Atrial fibrillation-related endocardial remodeling and 
dysfunction
As the number of studies investigating the endocardium in the 
setting of AF has increased, AF is being increasingly recognized to 
exhibit endocardial dysfunction and damage. With the onset of AF, 
ensuing inflammation increases the expression of cell adhesion 
molecules such as E-selectin on the endocardial surface.18) More-
over, anti-coagulant mechanism of the endocardium is attenuated 
when ET-1 is increased.7) Ultimately, a pro-thrombotic environment 
is formed in the fibrillating atria. Furthermore, inflammatory mole-
cules like C-reactive protein induce endocardial cells to increase the 
expression of PDGF.19) In response, fibroblasts proliferate and alter 
the extracellular matrix.20) Structural remodeling of the atria further 
increases the likelihood of thrombus formation. All of the mole-
cules mentioned are regulated by NO upstream.6)14) However, NO 
appears to be present in different expression levels between the LA 
and the RA.4) Hence, in this study, we measured the expression level 
of these molecules and examined whether differences in the ex-
pression level of NO translate into differences in the expression level 
of thrombosis-associated molecules to explain the differential th-
rombogenesis between the LA and the RA. According to several 
studies, the condition of an abnormality in the tissue factor, one of 
the three conditions in Virchow’s triad, is better fulfilled by the LA 
than the RA. Goldsmith et al.21) observed microscopic alterations of 
the two chambers and reported that cellular and intercellular per-
forations in the endocardium were more frequently seen in the LA. 
Modrego et al.22) reported observations at the molecular level, sug-
gesting that the RA is better protected from harmful agents than 
the LA as evidenced by higher expression of cytoprotective pro-
teins like heat shock protein 27 (Hsp27) and glutathione-S-trans-
ferase in the RAA. However, the extensive analysis of factors asso-
ciated with thrombogenesis in our study proved otherwise. The 
mRNA or protein levels of factors such as E-selectin, CD31, as well 
as ET-1 were not significantly different between the LA and the 
RA. Our findings enable us to exclude abnormality in the vessel wall 
as a cause for increased thrombi formation in the LA.
Pathophysiological differences between the left atrium and 
the right atrium in atrial fibrillation-associated 
thromboembolism
Even though both LA and RA can be seen fibrillating during AF, 
Table 4. Next generation sequencing of mRNAs associated with tissue thrombogenicity
LA (n=4) RA (n=4) p AF (n=4) SR (n=4) p
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 1.32±1.32 1.49±0.73 1.000 1.49±1.15 1.40±0.85 0.697 
Platelet/endothelial cell adhesion molecule 1 10.87±3.55 11.71±2.68 0.269 8.51±5.91 13.06±2.19 0.707 
E-selectin 2.93±0.05 5.66±0.06 0.348 2.87±0.10 5.70±0.07 0.368 
Nitric oxide synthase 1 (neuronal) 0.02±0.02 0.03±0.01 0.955 0.02±0.01 0.03±0.01 0.399 
Stromal cell-derived factor 2 4.69±3.00 4.44±2.89 0.547 4.32±3.38 4.68±2.73 0.741 
Endothelin-1 12.37±8.09 9.12±7.68 0.500 8.87±11.58 10.84±5.65 0.673 
Platelet-derived growth factor alpha polypeptide 4.93±3.22 5.56±4.14 0.639 4.20±3.95 6.01±3.72 0.946 
Myeloperoxidase 0.04±0.01 0.04±0.02 0.298 0.04±0.01 0.04±0.02 0.297 
Potassium intermediate/small conductance calcium-activated 
  channel, subfamily N, member 1 (KCNN1)
0.21±0.10 0.02±0.05 0.016 0.11±0.16 0.12±0.10 0.919 
mRNA: messenger ribonucleic acid, AF: atrial fibrillation, LA: left atrium, RA: right atrium, SR: sinus rhythm
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the LA, rather than the RA, is predominantly responsible for initia-
tion of fibrillatory activity as well as intracardiac thrombogenesis.23) 
If there is no significant difference in the tissue factors responsible 
for thrombogenicity, then what is the potential mechanism for the 
difference in thrombogenicity between the LA and the RA? There 
are several potential mechanisms for the LA-RA difference in throm-
boembolic risk. First, the RA appendage (RAA) is pyramidal in shape, 
whereas the LAA is a finger-like extension. The expression of tran-
scription factors and left-right differential signaling24) lead to a num-
ber of morphological differences between the LA and the RA.25) The 
difference in the shape carries multiple ramifications. The volume 
of the LAA is significantly smaller,26) and the LAA ostium is much nar-
rower than the RAA ostium.27) Ultimately, the differences in mor-
phology and junction with their respective atria cause undisturbed 
blood flow in the RAA and stasis in the LAA. Second, more exten-
sive remodeling of the LA may have resulted in a greater loss of atri-
al contractility on the left side of the heart, forcing the blood to pool 
to a greater extent when in the LA. The degree of fibrosis and extra-
cellular matrix remodeling was greater in the LAA than in the RAA.28) 
At the molecular level, the matrix metalloproteinase (MMP)-9 level 
was higher in the LAA than in the RAA, which explains the greater 
degradation of the extracellular matrix and subsequent chamber dil-
atation and wall thinning in the LA than in the RA.22) Third, due to 
the nature of connection of each chamber to the surrounding or-
gans, clinical consequences of thrombi from the two atria also dif-
fer. Lungs have thrombolytic mechanisms that can dissolve throm-
bi, and are rich in the collateral vascular network; hence thrombi 
from the RA may lead to little clinical consequence or subclinical 
pulmonary embolism. In contrast, however, brain has a sparse anas-
tomotic vascular network and has minimal antithrombotic mecha-
nism, thus making the thrombi originating in the LA more important 
from a clinical perspective as well as in further studies. 
Limitations
A small sample size and the selection bias might be the limita-
tions of this study. The atrial appendage tissues were taken based 
on the surgeon’s decision during the operation, and only those pa-
tients who underwent an atrial biopsy were included in this study. 
Both the RA and LA tissues were taken from the same 6 out of the 
25 enrolled patients. Although we included relatively homogeneous 
patients with mitral valve disease and the comparative results of 
these 6 patients were consistent to the overall analyses, it may have 
affected the results of this study. Although the main purpose of 
the current study was to perform a comparison between the LA and 
the RA, we could not compare volumes of the LA and RA based on 
imaging studies. Because the cardiac CT protocol was designed for 
left cardiac chamber evaluation and limited contrast agent filling in 
the RA, an accurate measurement of the RA volume was not pos-
sible in this patient population. 
In conclusion, in spite of more advanced subendocardial or matrix 
remodeling in the LA than in the RA, the biomarkers representing 
endocardial function were not significantly different between the 
RA and the LA in patients with mitral valvular AF.
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